pharma · Complement-mediated Hemolytic Diseases
Nanjing Chia-tai Tianqing
Nanjing Chia-tai Tianqing Pharmaceutical
Nanjing Chia-tai Tianqing is a pharma organization headquartered in CN. Primary therapeutic focus areas include Complement-mediated Hemolytic Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
NTQ5082 capsule
Phase 1 · small molecule · Complement-mediated Hemolytic Diseases
NTQ5082 capsule for Complement-mediated Hemolytic Diseases is a Phase 1 program (small_molecule) at Nanjing Chia-tai Tianqing Pharmaceutical with 1 ClinicalTrials.gov record(s).
Internal code NTQ5082-24102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Complement-mediated Hemolytic Diseases
- Status
- active
- Trials
- 1